Oncolytics Biotech (ONCY) Gains from Investment Securities (2010 - 2025)
Oncolytics Biotech's (ONCY) quarterly Gains from Investment Securities came in at $764420.0 in Q3 2025, up 555.37% year-on-year from $116640.1 in Q3 2024, and up 440.4% on a QoQ basis from $141455.6 in Q2 2025.
Oncolytics Biotech (ONCY) Gains from Investment Securities (2010 - 2025) Analysis & Trends
Oncolytics Biotech (ONCY) has 14 years of Gains from Investment Securities data on file, last reported at $764420.0 in Q3 2025.
- On a quarterly basis, Gains from Investment Securities rose 555.37% year-over-year to $764420.0 in Q3 2025; TTM through Sep 2025 was $803758.0, a 117.69% increase from a year earlier, with the FY2025 full-year figure at -$153000.0, up 86.91% from the prior year.
- Gains from Investment Securities for Q3 2025 stood at $764420.0, up from $141455.6 in the prior quarter.
- Over the last five years, Gains from Investment Securities for ONCY reached as high as $764420.0 in Q3 2025 and fell as low as -$3.6 million in Q4 2023.
- Historically, Gains from Investment Securities has averaged -$214181.0 across 5 years, with a median of -$30593.2 in 2022.
- Across the five-year window, Gains from Investment Securities sank 16761.18% in 2023 and soared 555.37% in 2025, its largest moves.
- Year by year, Gains from Investment Securities stood at -$39194.8 in 2021, then surged by 154.51% to $21364.4 in 2022, then sank by 16761.18% to -$3.6 million in 2023, then surged by 101.83% to $65142.3 in 2024, then surged by 1073.46% to $764420.0 in 2025.
- Per Business Quant data, the three most recent Gains from Investment Securities figures were $764420.0 in Q3 2025, $141455.6 in Q2 2025, and -$167260.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn |
| 10 | Oncolytics Biotech | 77.59 Mn | 77.59 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 764,420.02 |
| Sep 30, 2025 | 764,420.02 |
| Jun 30, 2025 | 141,455.65 |
| Jun 30, 2025 | 141,455.65 |
| Mar 31, 2025 | -167,259.95 |
| Mar 31, 2025 | -167,259.95 |
| Dec 31, 2024 | 65,142.27 |
| Dec 31, 2024 | 65,142.27 |
| Sep 30, 2024 | -167,869.23 |
| Sep 30, 2024 | -167,869.23 |
| Jun 30, 2024 | -171,818.03 |
| Jun 30, 2024 | -171,818.03 |
| Mar 31, 2024 | -644,896.38 |
| Mar 31, 2024 | -644,896.38 |
| Dec 31, 2023 | -3.56 Mn |
| Dec 31, 2023 | -3.56 Mn |
| Sep 30, 2023 | -384,154.19 |
| Sep 30, 2023 | -384,154.19 |
| Jun 30, 2023 | 79,656.41 |
| Jun 30, 2023 | 79,656.41 |